Clinical factors associated with serum copper levels and potential effect of sevelamer in hemodialysis patients

International Urology and Nephrology

Volumn 45, Issue 3, 2013, Pages 839-845

  Ikee, Ryota ^a   Tsunoda, Masataka ^a   Sasaki, Naomi ^a   Sato, Naritsugu ^a   Hashimoto, Nobuo ^a  

^a H N Medic Kitahiroshima ^*  (Japan)

Author keywords

Copper; Dyslipidemia; Hemodialysis; Inflammation; Oxidative stress; Sevelamer

Indexed keywords

C REACTIVE PROTEIN; COPPER; HOMOCYSTEINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MALONALDEHYDE; SEVELAMER;

ADULT; AGED; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; COPPER BLOOD LEVEL; CROSS-SECTIONAL STUDY; DYSLIPIDEMIA; FEMALE; HEMODIALYSIS; HUMAN; INFLAMMATION; NONHUMAN;

AGED; CHELATING AGENTS; COPPER; CROSS-SECTIONAL STUDIES; DYSLIPIDEMIAS; FEMALE; FOLLOW-UP STUDIES; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; OXIDATIVE STRESS; POLYAMINES; RENAL DIALYSIS; TIME FACTORS;

EID: 84879505125     PISSN: 03011623     EISSN: 15732584     Source Type: Journal    
DOI: 10.1007/s11255-012-0211-3     Document Type: Article

References (33)

1. Tapiero H, Townsend DM, Tew KD (2003) Trace elements in human physiology and pathology. Copper. Biomed Pharmacother 57:386-398
2. Walter RM Jr, Uriu-Hare JY, Olin KL et al (1991) Copper, zinc, manganese, and magnesium status and complications of diabetes mellitus. Diabetes Care 14:1050-1056
3. Bo S, Durazzo M, Gambino R et al (2008) Associations of dietary and serum copper with inflammation, oxidative stress, and metabolic variables in adults. J Nutr 138:305-310
4. Magalova T, Brtkova A, Bederova A, Kajaba I, Puchonova I (1994) Serum copper and zinc in industrial centers in Slovakia. Biol Trace Elem Res 40:225-235
5. Ferns GA, Lamb DJ, Taylor A (1997) The possible role of copper ions in atherogenesis: the Blue Janus. Atherosclerosis 133:139-152
6. Faraci FM, Didion SP (2004) Vascular protection: superoxide dismutase isoforms in the vessel wall. Arterioscler Thromb Vasc Biol 24:1367-1373
7. Shukla N, Maher J, Masters J, Angelini GD, Jeremy JY (2006) Does oxidative stress change ceruloplasmin from a protective to a vasculopathic factor? Atherosclerosis 187:238-250
8. Tonelli M, Wiebe N, Hemmelgarn B et al (2009) Trace elements in hemodialysis patients: a systematic review and meta-analysis. BMC Med 7:25
9. Takagi K, Masuda K, Yamazaki M et al (2010) Metal ion and vitamin adsorption profiles of phosphate binder ion-exchange resins. Clin Nephrol 73:30-35
10. Tsubakihara Y, Nishi S, Akiba T et al (2010) 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease. Ther Apher Dial 14:240-275
11. Kalantar-Zadeh K, McAllister CJ, Lehn RS, Lee GH, Nissenson AR, Kopple JD (2003) Effect of malnutrition-inflammation complex syndrome on EPO hyporesponsiveness in maintenance hemodialysis patients. Am J Kidney Dis 42:761-773
12. Panichi V, Rosati A, Bigazzi R et al (2011) Anaemia and resistance to erythropoiesis-stimulating agents as prognostic factors in haemodialysis patients: results from the RISCAVID study. Nephrol Dial Transplant 26:2641-2648
13. Locsey L, Papp L (1983) Study of trace elements in patients on haemodialysis. Int Urol Nephrol 15:289-295
14. Healy H, Reith D, Morgan C, Clague A, Westhuyzen J (2000) Are metalloproteins and acute phase reactants associated with cardiovascular disease in end-stage renal failure? Ann Clin Lab Sci 30:295-304
15. Navarro-Alarcon M, Reyes-Perez A, Lopez-Garcia H, Palomares-Bayo M, Olalla-Herrera M, Lopez-Martinez MC (2006) Longitudinal study of serum zinc and copper levels in hemodialysis patients and their relation to biochemical markers. Biol Trace Elem Res 113:209-222
16. Koca T, Berber A, Koca HB, Demir TA, Koken T (2010) Effects of hemodialysis period on levels of blood trace elements and oxidative stress. Clin Exp Nephrol 14:463-468
17. Veighey K, Booth J, Davenport A (2011) Does the choice of phosphate binder affect trace element levels in chronic kidney disease patients treated by regular haemodialysis? Nephrol Dial Transplant 26:1006-1010
18. Sondheimer JH, Mahajan SK, Rye DL et al (1988) Elevated plasma copper in chronic renal failure. Am J Clin Nutr 47:896-899
19. Ari E, Kaya Y, Demir H, Asicioglu E, Keskin S (2011) The correlation of serum trace elements and heavy metals with carotid artery atherosclerosis in maintenance hemodialysis patients. Biol Trace Elem Res 144:351-359
20. Higuchi T, Matsukawa Y, Okada K et al (2006) Correction of copper deficiency improves erythropoietin unresponsiveness in hemodialysis patients with anemia. Intern Med 45:271-273
21. Rounis E, Laing CM, Davenport A (2010) Acute neurological presentation due to copper deficiency in a hemodialysis patient following gastric bypass surgery. Clin Nephrol 74:389-392
22. Nishizawa Y, Shoji T, Kakiya R et al (2003) Non-high-density lipoprotein cholesterol (non-HDL-C) as a predictor of cardiovascular mortality in patients with end-stage renal disease. Kidney Int 63(Suppl 84):S117-S120
23. Shoji T, Masakane I, Watanabe Y, Iseki K, Tsubakihara Y, Committee of Renal Data Registry, Japanese Society for Dialysis Therapy (2011) Elevated non-high-density lipoprotein cholesterol (non-HDL-C) predicts atherosclerotic cardiovascular events in hemodialysis patients. Clin J Am Soc Nephrol 6:1112-1120
24. Uauy R, Olivares M, Gonzalez M (1998) Essentiality of copper in humans. Am J Clin Nutr 67(5 Suppl):952S-959S
25. Lin YF, Chien CT, Kan WC et al (2011) Pleiotropic effects of sevelamer beyond phosphate binding in end-stage renal disease patients: a randomized, open-label, parallel-group study. Clin Drug Investig 31:257-267
26. Chertow GM, Burke SK, Raggi P, Treat to Goal Working Group (2002) Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 62:245-252
27. Navarro-Gonzalez JF, Mora-Fernandez C, Muros de Fuentes M, Donate-Correa J, Cazana-Perez V, Garcia-Perez J (2011) Effect of phosphate binders on serum inflammatory profile, soluble CD14, and endotoxin levels in hemodialysis patients. Clin J Am Soc Nephrol 6:2272-2279
28. Ikee R, Tsunoda M, Sasaki N, Sato N, Hashimoto N (2012) Potential influence of sevelamer hydrochloride on responsiveness to erythropoiesis- stimulating agents in haemodialysis patients. Nephrology (Carlton) 17:225-229
29. Nakai S, Iseki K, Itami N et al (2012) Overview of regular dialysis treatment in Japan (as of 31 December 2009). Ther Apher Dial 16:11-53
30. Goto S, Fujii H, Kim JI, Fukagawa M (2010) Homocysteine and folic acid levels in hemodialysis patients treated with sevelamer hydrochloride. Clin Nephrol 73:420-425
31. Kirschbaum B (2000) Relationships between the copper and iron systems in hemodialysis patients and variables affecting these systems. Biol Trace Elem Res 77:13-24
32. Guo CH, Chen PC, Yeh MS, Hsiung DY, Wang CL (2011) Cu/Zn ratios are associated with nutritional status, oxidative stress, inflammation, and immune abnormalities in patients on peritoneal dialysis. Clin Biochem 44:275-280
33. Guo CH, Ko WS, Chen PC, Hsu GS, Lin CY, Wang CL (2009) Alterations in trace elements and oxidative stress in uremic patients with dementia. Biol Trace Elem Res 131:13-24